Sort   by:  
 Page size 
ProteomicsThe PDE4 inhibitor apremilast modulates ethanol responses in Gabrb1 S409A knock-in mice via PKA-dependent and independent mechanisms
We previously showed that the PDE4 inhibitor apremilast reduces ethanol consumption in mice by protein kinase A (PKA) and GABAergic mechanisms. Preventing PKA phosphorylation of GABAA 3 subunits partially blocked apremilast-mediated decreases in alcohol drinking. Here, we produced Gabrb1-S409A knock...
ORGANISM(S): Mus musculus (Mouse) 
2025-10-06 | PXD052839 | Pride
Gaba a receptor Mutany Apremilast Pka Gabrb1 Ethanol 
GenomicsA Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
PRJNA494869 | ENA
GenomicsCirculating Monocytes are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast
Circulating Monocytes are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast
PRJNA1078849 | ENA
TranscriptomicsA Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD).
ORGANISM(S): Homo sapiens 
2018-10-06 | GSE120899 | GEO
TranscriptomicsA phase 2, open label single arm study for evaluating safety & efficacy of apremilast in the treatment of cutaneous disease in patients with recalcitrant dermatomyositis.
Purpose: Studying the efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis. Studying the mechanism of action of apremilast in dermatomyositis by performing RNA sequencing and immunohistochemistry on skin biopsies before and after treatment. M...
ORGANISM(S): Homo sapiens 
2022-01-11 | GSE193276 | GEO
TranscriptomicsCirculating Monocytes are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast
Monocytes play a critical role in the inflammation associated with psoriasis, and their abnormalities have been reported as biomarkers of cardiovascular event risk, a psoriasis comorbidity. Monocytic cells in chronic inflammatory disorders express elevated levels of cAMP phosphodiesterase. Restoring...
ORGANISM(S): Homo sapiens 
2024-02-26 | GSE256275 | GEO
GenomicsA phase 2, open label single arm study for evaluating safety & efficacy of apremilast in the treatment of cutaneous disease in patients with recalcitrant dermatomyositis.
A phase 2, open label single arm study for evaluating safety & efficacy of apremilast in the treatment of cutaneous disease in patients with recalcitrant dermatomyositis.
PRJNA795623 | ENA
UnknownApremilast in Refractory Alopecia Areata.
Not available
S-EPMC6830030 | biostudies-literature
UnknownOff-label studies on apremilast in dermatology: a review.
Not available
S-EPMC6774908 | biostudies-literature
UnknownProtective roles of apremilast via Sirtuin 1 in atherosclerosis.
Not available
S-EPMC9276050 | biostudies-literature
Sort   by:  
 Page size